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Dual leucine zipper-bearing kinase (DLK) is a mixed-lineage
kinase family member that acts as an upstream activator of the
c-Jun N-terminal kinases. As opposed to other components of
this pathway, very little is currently known regarding the mech-
anisms by which DLK is regulated in mammalian cells. Here we
identify the stress-inducible heat shock protein 70 (Hsp70) as a
negative regulator of DLK expression and activity. Support for
this notion derives from data showing that Hsp70 induces the
proteasomal degradation of DLK when both proteins are co-
expressed in COS-7 cells. Hsp70-mediated degradation occurs
with expression of wild-type DLK, which functions as a consti-
tutively activated protein in these cells but not kinase-defective
DLK. Interestingly, the Hsp70 co-chaperone CHIP, an E3 ubiq-
uitin ligase, seems to be indispensable for this process since
Hsp70 failed to induceDLKdegradation inCOS-7 cells express-
ing a CHIP mutant unable to catalyze ubiquitination or in
immortalized fibroblasts derived from CHIP knock-out mice.
Consistentwith these data,wehave found that endogenousDLK
becomes sensitive to CHIP-dependent proteasomal degrada-
tion when it is activated by okadaic acid and that down-regula-
tion of Hsp70 levels with an Hsp70 antisense attenuates this
sensitivity. Therefore, our studies suggest that Hsp70 contrib-
utes to the regulation of activated DLK by promoting its CHIP-
dependent proteasomal degradation.
Dual leucine zipper-bearing kinase (DLK)2 is a serine/threo-
nine kinase that belongs to a family of mitogen-activated pro-
tein kinase kinase kinases, known as mixed-lineage kinases
(MLKs) (1). Members of this family, which also include MLK1,
MLK2, MLK3, MLK4, leucine zipper-bearing kinase, and
leucine zipper and sterile -motif kinase (1), are characterized
at the structural level by the presence of a catalytic domain
bearing amino acid motifs found in serine/threonine and tyro-
sine kinases and one or two leucine zipper motifs, which regu-
late their activity by mediating protein dimerization or oli-
gomerization (2–5). A number of other interesting motifs that
are likely important for protein binding have also been identi-
fied in specific members of the MLK family. For instance,
MLK2 and MLK3 contain a Src homology 3 (SH3) domain in
their N-terminal region that binds, respectively, the GTPase
dynamin and the Ste20-related protein kinaseHPK1 (6, 7). Both
MLK proteins also possess a functional Cdc42/Rac interactive
binding (CRIB)motif thatmediates associationwithCdc42 and
Rac1 in a GTP-dependent manner (8, 9).
The importance of the MLKs as signaling molecules is high-
lighted by the fact that these proteins act as key regulators of the
c-Jun N-terminal kinase (JNK) subgroup of mitogen-activated
protein kinases (1). Specifically, all MLK family members regu-
late the JNK pathway by phosphorylating and activating the
JNK direct upstream activators MKK4 and MKK7 (10–14). In
addition to their role in catalyzing JNK activation, MLKs are
also known to contribute to apoptosis in neuronal cells. Indeed,
when dominant negative forms of MLKs were expressed in
neuronal PC12 cells and sympathetic neurons, death caused by
nerve growth factor deprivation was severely inhibited (15).
Evidence supporting the involvement of theMLKs in apoptosis
also derives from studies with theMLK inhibitor CEP1347 (16),
which provides neuroprotection against numerous death-in-
ducing stimuli (17–19).
As is the case for the majority of MLK family members, rel-
atively little is known about themechanisms responsible for the
activation and regulation of DLK in mammalian cells. Current
evidence suggests that the leucine zipper domain of DLK plays
a role in the activation process, as deletion of this region pre-
vents dimerization, autophosphorylation, and stimulation of
the JNK pathway (20).Work from a number of laboratories has
also established that the regulation of DLK involves heterolo-
gous interactions with scaffolding and inhibitory proteins. The
binding of DLK to these proteins, in particular JNK-interacting
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protein (JIP)-1 and MAPK upstream kinase (MUK)-binding
inhibitory protein (MBIP), is likely to play an important role in
DLK regulation by preventing its dimerization (21–23).
Another importantmechanismbywhichDLK is proposed to be
regulated is through changes in its phosphorylation status.
Experimental evidence supporting the involvement of phos-
phorylation in DLK regulation derives from the observation that
oligomerization-dependent autophosphorylation is required for
activation ofDLK and stimulation of the JNK pathway (20). Fur-
thermore, other studies have revealed that DLK exists in part as
a phosphoprotein in vivo and that treatment of cells with oka-
daic acid, an inhibitor of protein phosphatases 1 and 2A, results
in accumulation of phosphorylated DLK (24). Finally, Nakata
et al. (25) recently demonstrated that DLK protein levels in
Caenorhabditis elegans are down-regulated by an E3 ubiquitin
ligase, termed RPM-1, which was found to stimulate DLK
ubiquitination.
In the current study we report that activated DLK either
exogenously or endogenously expressed is down-regulated by
the stress-inducible heat shock protein 70 (Hsp70), amolecular
chaperone that confers cytoprotection in response to various
stress stimuli (26–29). Our study also shows that Hsp70-de-
pendent DLK down-regulation is mediated by a proteasome-
dependent mechanism involving the CHIP ubiquitin ligase.
Thus, our results support a role for Hsp70 and CHIP as impor-
tant regulators of DLK protein levels.
EXPERIMENTAL PROCEDURES
Chemicals, Reagents, and Antibodies—The proteasome inhibi-
tor lactacystin and the rabbit polyclonal antibody against actin
were purchased from Sigma-Aldrich. The mouse monoclonal
antibody for the detection of phospho-JNK and the rabbit poly-
clonal antibody insensitive to the phosphorylation state of JNK
were purchased from Cell Signaling Technology Inc. (Beverly,
MA). Themousemonoclonal antibodies against the T7 and the
hexahistidine tag sequences were from Novagen, Inc. (Madi-
son, WI) and Invitrogen, respectively. The anti-Myc mono-
clonal antibody (clone 9E10) and okadaic acid were obtained
from Calbiochem-Novabiochem. The rabbit polyclonal anti-
bodies against DLK, Hsp70, Hsp27, Hsp40, Hsp60, Hsc70,
Hsp90, Hsp90, and CHIP were described previously (30–
33). The rabbit anti-ubiquitin antibody was purchased from
Rockland Immunochemicals, Inc. (Gilbertsville, PA). Recombi-
nant Hsp70 was purchased from Stressgen Biotechnologies
Corp. (Victoria, BC, Canada). Cell culture reagents were from
Invitrogen,HyClone Laboratories (Logan, UT), CambrexCorp.
(East Rutherford, NJ), or BIOSOURCE International Inc.
(Camarillo, CA).
Cell Culture—COS-7 cells were cultured in Dulbecco’s mod-
ified Eagle’s medium (DMEM) supplemented with 10% (v/v)
heat-inactivated fetal bovine serum (FBS), 100 units/ml peni-
cillin, 100 g/ml streptomycin, and 25 g/ml amphotericin B.
Transformed lung fibroblasts derived from CHIP/ and
CHIP/ mice were also maintained in DMEM plus 10% FBS.
Plasmids and Transfection—The T7-tagged DLK expression
vector was generously provided by Dr. S. Hirai (Yokohama City
University School of Medicine). The expression vector for
T7-tagged catalytically inactiveDLKwas produced by replacing
the invariant lysine at position 185 within kinase subdomain II
with arginine using the Stratagene QuikChange site-directed
mutagenesis kit (La Jolla, CA). The entire coding region of the
cloned gene for human hsp70 (34) was inserted into a mamma-
lian expression vector under the control of the cytomegalovirus
promoter (CMV5). A mutant form of Hsp70 lacking the ATP
binding domain (Hsp70ABD) was constructed with the
Hsp70 expression vector by in-frame deletion of amino acid
residues 120–428 of the published human Hsp70 sequence
(34). pCW8 (expressing Myc-tagged ubiquitin K48R) was a gift
from Dr. R. Kopito (35). The pcDNA3 expression plasmids
encoding wild-type Myc-tagged CHIP (Myc-CHIP) and its
U-box deletion mutant (Myc-CHIPE4) have been described
previously (36). The antisense hsp70 pcDNA3 plasmid, con-
taining a 500-base pair fragment of the human inducible hsp70
cDNA in the antisense orientation (974–475), was a kind gift of
Dr. M. Jäättela (37). For gene transfer experiments, COS-7,
CHIP/, andCHIP/ cells in exponential growth phasewere
seeded at 2.5  105 viable cells/60-mm dish and allowed to
recover for 24 h. Thereafter, cells were transfected or cotrans-
fected with the different expression vectors mentioned above
using FuGENE 6 transfection reagent (Roche Diagnostics).
Cells were harvested and processed for immunoblot analysis
48 h after transfection. When indicated, medium was removed
48 h after transfection, and cells were treated with lactacystin
(10M) and/or okadaic acid (400 nM) in 3ml of DMEM supple-
mented with 10% (v/v) heat-inactivated FBS, 100 units/ml pen-
icillin, 100 g/ml streptomycin, and 25 g/ml amphotericin
B/60 mm at 37 °C. Then cells were harvested and processed for
further analyses.
Preparation of Cell Lysates and Immunoblotting—Cells were
lysed for 30 min at 4 °C in 15 mM Tris-HCl, pH 7.4, 1% Triton
X-100, 0.5% sodium deoxycholate, 0.2% SDS, 150 mM NaCl, 1
mM EGTA, 1 mM MgCl2, 1 mM phenylmethylsulfonyl fluoride
(PMSF), 1 g/ml leupeptin, and 1 g/ml aprotinin. Lysates
were clarified by centrifugation (13,000 rpm for 10min at 4 °C),
and the concentration of total protein in the supernatant frac-
tion was quantified by the modified Bradford protein assay
(Bio-Rad). For immunoblotting, equal amounts of proteins
were fractionated on 10% reducing SDS-PAGE and transferred
onto polyvinylidene difluoride membranes (Roche Diagnos-
tics) using a semidry transfer apparatus (Hoefer Scientific
Instruments). Membranes were blocked overnight at 4 °C in 20
mM Tris, pH 7.5, 150 mM NaCl, 0.1% Tween 20 containing 5%
skimmilk powder before incubation with the primary antibody
for 1 h at room temperature. Immunoreactive bands were
detected by enhanced chemiluminescence using secondary
horseradish peroxidase-conjugated antibodies (ECL Plus
Western blotting kit, Amersham Biosciences).
Immunoprecipitation—Cells were lysed for 30 min at 4 °C in
50mMTris-HCl, pH 7.4, 150mMNaCl, 5 mM EDTA, 1% Triton
X-100, 50 mM NaF, 0.2 mM Na3VO4, 1 mM PMSF, 1 g/ml
leupeptin, and 1g/ml aprotinin. Lysates were clarified by cen-
trifugation (13,000 rpm for 10 min at 4 °C), and the concentra-
tion of total protein in the supernatant fraction was quantified
using themodified Bradford protein assay (Bio-Rad). Typically,
500 g of protein extracts were incubated for 4 h at 4 °C with
constant rotationwith the primary antibody andproteinA-aga-
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rose beads. Immune complexes were collected by centrifuga-
tion (13,000 rpm for 1 min) and washed three times with lysis
buffer. The resulting pellet was resuspended in 2 SDS-PAGE
sample buffer, boiled for 5min, frac-
tionated on 10% SDS-PAGE, and
processed for immunoblot analysis
as described above.
In Vitro Interaction Assay—The
full-length coding sequence of wild-
type DLK was inserted in-frame
with a His-tag sequence in the
pTriEx-4 expression vector (Nova-
gen) for production of recombinant
proteins using the TNT T7 Cou-
pled Reticulocyte Lysate system
(Promega Corp., Madison, WI).
After nonradioactive translation
His-tagged wild-type DLK was
incubated for 2 h at 30 °C alone or
in combination with recombinant
Hsp70 (1g) in 50mMTris-HCl, pH
7.4, 150 mM NaCl, 5 mM EDTA, 1%
Triton X-100, 1 mM PMSF, 1 g/ml
leupeptin, and 1 g/ml aprotinin.
Proteins were then subjected to
immunoprecipitation with the anti-
Hsp70 antibody, and the resulting
immunocomplexes were analyzed
by immunoblotting with either the
anti-Hsp70 or anti-His antibody.
Pulse-ChaseAnalysis—COS-7cells
transiently expressing T7-tagged
wild-type DLK in the presence or
absence of Hsp70 were starved in
DMEMplus0.5%FBSwithoutmethi-
onine and cysteine for 16 h and then
metabolically labeled with [35S]me-
thionine/cysteine (Easy TagTM
EXPRESS,PerkinElmerLifeSciences)
for 45 min. Subsequently, cells were
chased in nonradioactivemedium for
the times indicated, lysed, and sub-
jected to immunoprecipitation with
the anti-T7 antibody. Immunocom-
plexes were resolved by SDS-PAGE
and visualized by autoradiography.
Immunocomplex Kinase Assay for
DLK—Cultures of CHIP/ and
CHIP/ cells were incubated in
the absence or presence of okadaic
acid (400 nM) and lactacystin (10
M) before homogenization in lysis
buffer (50mMTris-HCl, pH 7.4, 150
mM NaCl, 5 mM EDTA, 1% Triton
X-100, 50mMNaF, 0.2mMNa3VO4,
1mM PMSF, 1 g/ml leupeptin, and
1g/ml aprotinin). The lysateswere
clarified by centrifugation, and the
concentration of total protein in the supernatant fraction was
quantified using themodifiedBradford protein assay (Bio-Rad).
Typically, 600 g of protein extract were incubated for 2 h at
FIGURE 1. Hsp70 down-regulates the expression of DLK. A, COS-7 cells were transiently transfected with an
empty vector (3 g) or with an expression construct (3 g) encoding T7 epitope-tagged wild-type or kinase-
defective (K185R) DLK. At 48 h after transfection, cells were lysed and processed for immunoblotting with
antibodies to either the T7 epitope, Hsp70, Hsp27, Hsp40, Hsp60, Hsc70, Hsp90, Hsp90, or phosphorylated
JNK. The total level of JNK in cells was also analyzed by immunoblotting (WB) with a specific antibody. B, COS-7
cells were transfected with an expression vector (0.5 g) encoding T7 epitope-tagged wild-type or kinase-
defective (K185R) DLK either alone or together with an expression construct for human Hsp70 (0.5 g). At 48 h
after transfection, cells were lysed and processed for immunoblotting with antibodies to either the T7 tag or
Hsp70. As a control for protein loading, immunoblots were probed in parallel with an antibody targeting actin.
Densitometry analysis was used to determine the relative levels of DLK expression in the absence or presence
of Hsp70. The total amount of plasmid was kept constant in each transfection condition by including an empty
vector. C, COS-7 cells were transiently transfected with a plasmid (0.5 g) for T7-DLK either alone or together
with a vector (0.5 g) for Hsp70 or Hsp70ABD. At 48 h after transfection cells were lysed and processed for
immunoblotting with antibodies to either the T7 tag or Hsp70. As a control for protein loading, immunoblots
were probed in parallel with an anti-actin antibody. The total amount of plasmid was kept constant in each
transfection condition by including an empty vector. The data in this figure and all the other figures are
representative of at least three independent experiments.
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4 °C with constant rotation using a polyclonal antibody against
DLK (30) and protein A-Sepharose beads. After incubation, the
immunocomplexes were washed 3 times with lysis buffer and 3
times with kinase buffer (10 mM Tris-HCl, pH 7.4, 150 mM
NaCl, 10 mM MgCl2, 0.5 mM dithiothreitol, 0.1 mM PMSF, 0.2
mM sodium orthovanadate, 1 g/ml leupeptin, and 1 g/ml
aprotinin). Immunocomplex kinase assays were performed by
incubating the immune complexes in 40 l of kinase buffer
containing 2.5 Ci of [-32P]ATP (Amersham Biosciences), 25
MATP, and 1g ofmyelin basic protein as a substrate. After a
20-min incubation at 30 °C, the reaction was stopped by adding
an appropriate volume of 6 SDS-PAGE sample buffer and
boiling for 5 min. Phosphorylated proteins were visualized by
autoradiography after fractionation by SDS-PAGE.
RESULTS
Down-regulation of DLK by Hsp70—During the course of a
study recently conducted in our laboratory, we noticed that
overexpression of wild-type DLK inMCF-7 human breast can-
cer cells resulted in the accumulation of a protein with amolec-
ular weight (Mr) of 70,000 (p70), as revealed by Coomassie
Blue staining of cell extracts fractionated on reducing SDS-
PAGE. This protein bandwas excised from the gel and analyzed
by tandemmass spectrometry at the EasternQuebec Proteomic
Center (Université Laval, Québec, Canada). A correlative
search of the NCBI Protein Data base with the peptide product
ion spectra generated by tandem mass spectrometry identified
p70 as the stress-inducible protein Hsp70, a molecular chaper-
one that has been shown to protect cells against the potentially
fatal consequences of diverse physiological and environmental
insults (26, 27). This result was subsequently confirmed by
immunoblot analysis of total proteins isolated from MCF-7
cells overexpressing DLK with an antibody specific for the
inducibleHsp70 protein (31). To determinewhetherDLKover-
expression could elicit a similar induction of Hsp70 in another
cell system, we transfected COS-7 cells with an expression vec-
tor encoding a T7 epitope-tagged form of wild-type DLK. At
48 h after transfection cells were lysed and processed for immu-
noblot analyses using either anti-T7 or anti-Hsp70 antibodies.
The data presented in Fig. 1A demonstrate that overexpressed
DLK, which functions as a constitutively activated protein able
to induce phosphorylation of endogenous JNK, substantially
increased the levels of endogenousHsp70when comparedwith
cells transfected with an empty vector. Interestingly, this effect
is specific for Hsp70, because expression of the other Hsps
examined, including Hsp27, Hsp40, Hsp60, Hsc70, Hsp90,
and Hsp90, was not changed in DLK-transfected cells. More-
over, although it was expressed at levels comparable with wild-
type DLK, a catalytically inactive T7-tagged DLK mutant did
not influence the expression of any Hsps in transfected cells.
Thus, these results confirm that the ectopic expression of DLK
in COS-7 cells is sufficient to up-regulate in a specific manner
Hsp70 protein levels and suggest that DLK kinase activity is
required for Hsp70 induction.
To investigate the physiological relevance of Hsp70 induc-
tion inDLK-transfected cells, we next assayed the effects of this
molecular chaperone on the steady-state levels of wild-type
and kinase-defective T7-DLK in COS-7 cells co-transfected
with an expression plasmid for humanHsp70. After transfection,
cells were lysed and processed for immunoblot analysis with an-
ti-T7 and anti-Hsp70 antibodies. Results shown in Fig. 1B reveals
that Hsp70 co-expression, as demonstrated by the immunoblot
data, reduces by 80% the abundance of wild-type T7-DLK in
transfected cells. In contrast, the levels of the catalytically inactive
formof T7-DLK remained constant in response toHsp70 overex-
pression. These data indicate that wild-type T7-DLK undergoes
down-regulation mediated at least in part by its own activity in
cells which overexpressed Hsp70.
Because Hsp70 is composed of two functionally distinct
domains, an N-terminal ATPase domain responsible for its
protein folding function and a C-terminal peptide-binding
domain that specifically binds both unfolded and folded sub-
strates (28, 38), we asked whether the ATPase activity of Hsp70
could play a role inDLKdown-regulation. To this endwe trans-
fected COS-7 cells with the T7-tagged DLK expression con-
struct either alone or together with a plasmid encoding aHsp70
deletion mutant that lacks the ATPase domain (amino acids
120–428, Hsp70ABD) and measured the protein levels of
DLK in these cells byWestern blot analysis (Fig. 1C). Aswas the
case for wild-type Hsp70, overexpression of Hsp70ABD also
results in a dramatic decrease in ectopic DLK protein levels,
indicating that the ATPase activity of Hsp70 is not essential to
promote the down-regulation of DLK.
Hsp70 Associates with Wild-type DLK in Intact Cells but Not
in Vitro—As an approach to explore the mechanism by which
Hsp70 down-regulates DLK protein levels, we first examined
whether these proteins could associate physically in intact cells.
For this purpose, COS-7 cells transiently transfected with T7-
tagged DLKwere subjected to immunoprecipitation with anti-T7
antibody, and the resultant immunocomplexes were examined by
Westernblot analysisusing theanti-Hsp70antibody (Fig. 2A).The
immunoblot data reveals that endogenous Hsp70 associates with
wild-type T7-DLK in COS-7 cells. Interestingly, this association
FIGURE 2. Hsp70 associates with DLK in intact cells but not in vitro. A,
COS-7 cells were transiently transfected with empty vector (1 g) or expres-
sion plasmids for either T7-tagged wild-type DLK (1 g) or T7-tagged kinase-
defective (K185R) DLK (1 g). At 48 h after transfection cells were lysed and
immunoprecipitated (IP) with anti-T7 antibody. Immune complexes were
then subjected to Western blotting (WB) with antibodies to Hsp70 or the T7
tag. B, His-tagged DLK was incubated either alone or in combination with
recombinant Hsp70 for 2 h at 30 °C. After incubation proteins were subjected
to immunoprecipitation with the anti-Hsp70 antibody, and the resulting
immunocomplexes were analyzed by Western blotting using an antibody
against Hsp70 or the His tag. The presence of His-DLK and/or Hsp70 in input
material (5%) was verified by Western blotting with the same antibodies.
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appears to be regulated by DLK kinase activity, since the catalyti-
cally inactive T7-tagged DLKmutant did not co-immunoprecipi-
tate endogenous Hsp70 (Fig. 2A).
As a logical extension to thesedata,wenext sought to analyze in
vitro whether Hsp70 could interact directly with DLK. To do so
recombinant His-tagged DLK, produced by in vitro translation,
was incubated either alone or in combination with recombinant
Hsp70. After incubation, proteins were subjected to immunopre-
cipitationanalyseswith the anti-Hsp70antibody, and the resulting
complexes were probed with either the anti-Hsp70 or anti-His
antibody. The results shown in Fig. 2B indicates thatHis-DLKwas
not found in Hsp70 immunoprecipitates under these conditions.
Taken together, these results suggest that the interactionobserved
betweenHsp70 andwild-typeDLK inCOS-7 cells is weak or indi-
rect andpossibly involves theparticipationof at least anothermol-
ecule that could bridge or stabilize this interaction.
Hsp70 Reduces the Half-life of Nascent DLK—Given the ob-
servation that the steady-state levels of wild-type DLK were re-
duced in cells co-expressingHsp70,wenext askedwhetherHsp70
could affect the turnover ofDLK.To test this hypothesiswe deter-
mined the half-life of DLK in the presence or absence ofHsp70 by
using pulse-chase experiments. Cells transfected with T7-tagged
DLK either alone or together with Hsp70 were metabolically la-
beled for 45 min with a mixture of [35S]methionine and [35S]cys-
teine and then chased with unlabeled medium for various time
periods. Subsequently,T7-DLKwas immunoprecipitatedwith the
anti-T7 antibody, resolved in SDS-
PAGE, and visualized by autoradiog-
raphy. As shown in Fig. 3, similar
quantities of newly synthesized T7-
DLK were detected at chasing time 0
in COS-7 cells transiently co-trans-
fected with or without Hsp70. How-
ever, in the presence of Hsp70 the
half-life of T7-DLK was reduced by
greater than50%.Thus, our data indi-
cate that overexpressed Hsp70 dra-
matically enhances thedegradationof
DLK in COS-7 cells.
Wild-type but Not Kinase-defective
DLK Is an Hsp90 Client Protein—A
large number of signaling proteins in
mammalian cells is known to associ-
ate with a multichaperone complex
consisting of Hsp70, Hsp90, and dif-
ferent co-factors (39).This chaperone
system plays a major role not only in
the folding and maturation of client
proteins but also in their degradation
depending on the set of co-factors
(39). Because wild-type T7-tagged
DLK was found associated with
Hsp70, we examined whether endog-
enous Hsp90 also forms a complex
with this protein in transiently trans-
fected COS-7 cells. By analogy to the
data presented above, we found that
endogenousHsp90 could be detected
FIGURE 3. Hsp70 reduces the half-life of DLK. COS-7 cells were transfected with
an expression vector (0.5 g) encoding T7 epitope-tagged wild-type DLK either
alone or together with an expression construct for human Hsp70 (0.5 g). At 48 h
after transfection cells were serum-starved for 16 h, pulsed for 45 min with 25
Ci/ml [35S]methionine/cysteine, and then chased for the indicated time periods
in DMEM containing 10% FBS. 35S-Labeled T7-DLK was immunoprecipitated (IP)
with the anti-T7 antibody, fractionated by SDS-PAGE, and visualized by autora-
diography. The relative amount of newly synthesized T7-DLK was determined by
liquid scintillation counting of the labeled T7-DLK protein band cut from the gel.
The total amount of plasmid was kept constant in each transfection condition by
including an empty vector.
FIGURE 4. Wild-type but not kinase-defective DLK is an Hsp90 client protein. A, COS-7 cells were
transiently transfected with empty vector (1 g) or expression constructs for either T7-tagged wild-type
DLK (0.5 g) or T7-tagged kinase-defective (K185R) DLK (0.5 g) in the presence or absence of Hsp70 (0.5
g). At 48 h after transfection, cells were lysed and processed for immunoprecipitation (IP) with the
anti-T7 antibody. The immunocomplexes were then subjected to Western blotting (WB) with anti-Hsp90
antibody. DLK and Hsp70 protein levels were determined by probing the lysates with the anti-T7 and
anti-Hsp70 antibodies, respectively. As a control for protein loading, immunoblots were probed in parallel
with an anti-actin antibody. The total amount of plasmid was kept constant in each transfection condition
by including an empty vector. B, COS-7 cells transfected with either T7-tagged wild-type (1 g) or kinase-
defective (K185R) DLK (1 g) were exposed for the indicated time periods to geldanamycin (GA) and then
processed for Western blotting with anti-T7 antibody. As a control for protein loading, immunoblots were
probed in parallel with an anti-actin antibody.
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in immunoprecipitates of T7-tagged wild-type but not kinase-de-
fectiveDLK (Fig. 4A). Becausebinding toHsp90 is required for the
stability and/or activity of certain protein kinases (39), we won-
dered whether Hsp90 association with wild-type DLK could be
altered by co-expression of Hsp70. Results shown in Fig. 4A dem-
onstrated that overexpressedHsp70 enhances rather than inhibits
the interactionofwild-typeDLKwithendogenousHsp90. In these
conditions,Hsp70was also able to induce the formation of a com-
plex between the kinase-defective DLK variant and endogenous
Hsp90. Thus, it appears that down-regulation of wild-type DLK
caused by Hsp70 is not attributable to disruption of its binding to
Hsp90.
To further examine the influence of Hsp90 on the stability of
DLK, we monitored the steady-state levels of both wild-type
and kinase-defective T7-DLK in COS-7 cells exposed for vari-
ous times to the ansamycin antibiotic geldanamycin, which
specifically binds to Hsp90 and usually promotes the degrada-
tion of its client proteins (40). Treatment of transfected cells
with 5M geldanamycin for 18 h led to the complete disappear-
ance of wild-type DLK, whereas no significant effect on the
expression of its kinase-defective counterpart was observed
under the same conditions (Fig. 4B). Immunoblots processed in
parallel with an antibody against actin ensured that this trend
was not attributed to variations in the loading of protein sam-
ples. These data are, therefore, consistent with the idea that
wild-type but not kinase-defective DLK requires Hsp90 for sta-
bility in COS-7 cells.
DLK Is Subject to Proteasome-dependent Degradation in
Hsp70-transfected Cells—To further characterize the mecha-
nism underlying DLK down-regulation in cells overexpressing
Hsp70, we asked whether DLK could serve as a substrate of the
proteasomal degradationmachinery, which is linked to the heat
shock protein network (36, 41–44). To test this we transfected
COS-7 cells with a vector expressing T7-tagged DLK alone or
together with an expression plasmid for Hsp70. At 48 h after
transfection, cells were incubated with and without the protea-
some inhibitor lactacystin before being processed for immuno-
blotting with anti-T7 and anti-Hsp70 antibodies. As shown in
Fig. 5A, lactacystin treatment substantially suppresses the dis-
appearance of T7-DLK in Hsp70-transfected cells, thereby
suggesting that the 26 S proteasome might be responsible at
least in part for the down-regulation of DLK in response to
Hsp70 overexpression.
Because the 26 S proteasome generally degrades intracellular
proteins in a ubiquitin-dependent manner (45), we next under-
took experiments to determine the role of ubiquitination in
Hsp70-mediated degradation of T7-DLK. For this purpose we
examined by immunoblot analyses the steady-state level of
exogenously expressed T7-DLK in COS-7 cells that were co-
transfected with Hsp70 and increasing amounts of a Myc-
tagged ubiquitin mutant (K48R), which prevents the synthesis
of polyubiquitin chains and inhibits degradation by the protea-
some (35). As depicted in Fig. 5B, transfection of the K48R
mutant ubiquitin suppresses the Hsp70-induced down-regula-
tion of T7-DLK in a dose-dependent manner. This result
implies that Hsp70 promotes the proteasomal degradation of
DLK by a mechanism involving polyubiquitination.
CHIP Is Required for Hsp70-mediated Degradation of DLK—
The ability of Hsp70 to promote proteasomal degradation is
mediated at least in part by its interaction with the co-chaper-
one CHIP, an E3 ubiquitin ligase of the U-box protein family
(33, 46). To test the hypothesis thatCHIP is required forHsp70-
mediated degradation of DLK, we first examined by coimmu-
noprecipitation assay whether endogenous CHIP associates
with wild-type DLK transiently transfected in COS-7 cells.
These studies showed that CHIP is present in immunoprecipi-
tates of T7-tagged wild-type DLK (Fig. 6A). Interestingly, CHIP
FIGURE 5. Proteasome inhibition prevents the down-regulation of DLK in
Hsp70-transfected cells. A, COS-7 cells were transfected with empty vector
(1 g) or expression plasmids for either T7-tagged DLK (0.5 g), Hsp70 (0.5
g) or T7-tagged DLK (0.5 g) and Hps70 (0.5 g). At 48 h after transfection
cells were left untreated or were treated with 10 M lactacystin for 3 h. After
incubation cells were lysed and processed for immunoblotting with anti-T7 or
anti-Hsp70 antibodies. As a control for protein loading, immunoblots (WB)
were probed in parallel with an anti-actin antibody. B, COS-7 cells were tran-
siently transfected with a plasmid (0.5 g) for T7-DLK either alone or together
with a vector (0.5 g) for Hsp70 in the absence or presence of increasing
amounts (0.5, 1, 2, and 4 g) of an expression construct for a Myc-tagged
ubiquitin mutant (K48R). At 48 h after transfection, cells were lysed and pro-
cessed for immunoblotting with anti-T7 or anti-Hsp70 antibodies. As a con-
trol for protein loading, immunoblots were probed in parallel with an anti-
actin antibody. The total amount of plasmid was kept constant in each
transfection condition by including an empty vector.
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association with DLK seemed to depend onDLK kinase activity
becauseCHIPwas not co-immunoprecipitatedwith the kinase-
defective DLK mutant even though this variant was expressed
at levels similar to that of its wild-type counterpart.
In the next series of experiments wemeasured the steady-state
levels of T7-DLK inCOS-7 cells that were transfectedwithHsp70
or co-transfected with Hsp70 and a
mutant form of CHIP lacking ubiq-
uitin ligase activity (Myc-CHIPE4).
This mutant has been previously
shown to act in a dominant-negative
manner to block the ubiquitination
and degradation of CHIP substrates,
such as the glucocorticoid receptor
(36) and the cystic-fibrosis trans-
membrane conductance regulator
(47).Asexpected fromtheabovedata,
expression of Hsp70 greatly reduces
the steady-state levels of T7-DLK in
transfected cells (Fig. 6B). However,
inhibition of endogenous CHIP
activity by overexpression of its
U-box mutant almost completely
antagonizes the effects of Hsp70 on
T7-DLK, suggesting that Hsp70
inducesDLKdegradation inaCHIP-
dependent manner.
To further confirm a role for CHIP
in Hsp70-mediated degradation of
DLK, we compared the steady-state
levels of T7-tagged DLK in CHIP/
and CHIP/ cells that have been
transiently transfected with Hsp70.
Consistent with the results obtained
in COS-7 cells, the level of ectopically
expressedwild-typeDLKwas consid-
erably reduced in CHIP/ cells co-
expressing Hsp70, whereas that of ki-
nase-defective DLK remained
constant (Fig. 6C). Importantly, nei-
ther wild-type nor kinase-defective
DLK steady-state levels were affected
by expression of Hsp70 in CHIP/
cells. However, reintroduction of
CHIP in CHIP/ cells led to a dra-
matic decrease in the steady-state lev-
els of T7-tagged wild-type DLK, and
this was further enhanced when the
Hsp70 expression construct was
added to the transfection mixture
(Fig. 6D). As expected, down-regula-
tion of DLK protein expression in
these cells was accompanied by a re-
duction in phosphorylation but not
protein level of JNK. Thus, these data
suggest thatCHIP is essential in regu-
lating the Hsp70-induced degrada-
tion of active DLK.
In Its Active Form, Endogenous DLK Undergoes CHIP-
dependent Ubiquitination and Degradation—After having
observed in preliminary experiments that both CHIP/ and
CHIP/ cells express endogenous levels of DLK, we pro-
ceeded to investigate whether endogenous DLK could be sub-
ject to CHIP-dependent ubiquitination and degradation. To do
FIGURE 6. CHIP is required for Hsp70-mediated DLK degradation. A, COS-7 cells were transiently trans-
fected with empty vector (1 g) or expression plasmids for either T7-tagged wild-type DLK (1 g) or T7-tagged
kinase-defective (K185R) DLK (1 g). At 48 h after transfection, cells were lysed and immunoprecipitated (IP)
with anti-T7 antibody. Immune complexes were then subjected to Western blotting (WB) with antibodies to
CHIP. DLK protein levels were determined by probing the lysates with the anti-T7 antibody. As a control for
protein loading, immunoblots were probed in parallel with an anti-actin antibody. B, COS-7 cells were tran-
siently transfected with a plasmid (0.5 g) for T7-DLK either alone or together with a vector (0.5 g) for Hsp70
in the absence or presence of an expression construct (1 g) for an Myc-tagged CHIP mutant lacking ubiquitin
ligase activity (Myc-CHIPE4). At 48 h after transfection cells were lysed and processed for immunoblotting
with anti-T7, anti-Hsp70, or anti-Myc antibodies. As a control for protein loading, immunoblots were probed in
parallel with an anti-actin antibody. The total amount of plasmid was kept constant in each transfection
condition by including an empty vector. C, CHIP/ and CHIP/ cells were transiently transfected with expres-
sion constructs for either T7-tagged wild-type DLK (0.5 g) or T7-tagged kinase-defective (K185R) DLK (0.5 g)
in the presence or absence of Hsp70 (0.5 g). At 48 h after transfection, cells were lysed and processed for
immunoblotting with anti-T7, anti-Hsp70, or anti-CHIP antibodies. As a control for protein loading immunob-
lots were probed in parallel with an anti-actin antibody. The total amount of plasmid was kept constant in each
transfection condition by including an empty vector. D, CHIP/ cells were transiently transfected with a
plasmid (0.5 g) for T7-DLK either alone or together with a vector (0.5 g) for Hsp70 and an expression
construct (2 g) encoding a Myc-tagged wild-type form of CHIP. At 48 h after transfection cells were lysed and
processed for immunoblotting with anti-T7, anti-Hsp70, or anti-Myc antibodies. The level of phosphorylated
(p) and total JNK in these cells was also analyzed by immunoblotting with specific antibodies. As a control for
protein loading, immunoblots were probed in parallel with an anti-actin antibody. The total amount of plasmid
was kept constant in each transfection condition by including an empty vector.
Hsp70 and CHIP Act as Negative Regulators of DLK Protein Levels
OCTOBER 20, 2006 • VOLUME 281 • NUMBER 42 JOURNAL OF BIOLOGICAL CHEMISTRY 31473
so CHIP/ and CHIP/ cells were incubated with and with-
out the proteasome inhibitor lactacystin to prevent degradation
of ubiquitinated proteins. Lysates prepared from these cells
were then subjected to immunoprecipitation analyses with an
anti-DLK antibody (30), and the resulting immunocomplexes
were probed with an anti-ubiquitin antibody. Because DLK
kinase activity seems to be required for degradation, as sug-
gested by our results with ectopically expressedDLK, cells were
also exposed to the serine/threonine phosphatase inhibitor
okadaic acid before being processed for immunoprecipitation
to favor activation of endogenous DLK. Okadaic acid was cho-
sen as a potential activator of DLK based on the findings of
Mata et al. (24), who have observed accumulation of phospho-
rylated DLK in aggregating neural-glial cultures after exposure
to this compound. Results shown in Fig. 7 indicate that endog-
enous DLK was neither ubiquitinated nor degraded in
CHIP/ cells cultured in the presence of okadaic acid at a dose
inducing its activation, as can be seen by theDLK immunocom-
plex assay. By contrast, in CHIP/ cells a reduction of endog-
enous DLK levels was observed after activation by okadaic acid.
Treatment of these cells with lactacystin before supplementing
the culturemediumwith okadaic acid was sufficient to stabilize
endogenous DLK and promote the accumulation of immuno-
reactive bands that migrate as a high molecular mass smear,
likely corresponding to DLK molecules associated with ubiq-
uitin chains of different lengths. Thus, these results support the
notion that endogenous DLK undergoes ubiquitination and
degradation in CHIP/ cells when it is activated by okadaic
acid.
Down-regulation of Endogenous Hsp70 Impairs the CHIP-de-
pendent Proteasomal Degradation of Active DLK—To investi-
gate the role of Hsp70 in CHIP-dependent degradation of
endogenous DLK, we examined whether inhibition of Hsp70
expression could result in DLK stabilization. Accordingly,
CHIP/ and CHIP/ cells were transiently transfected with
either an empty vector or anHsp70 antisense construct capable
of inhibiting selectively the expression of Hsp70 (37), and then
the cellswere incubatedwith okadaic acid for 2 h to induceDLK
activation. In some cases, transfected cells were also heat-
shocked at 43 °C for 2 h and then recovered at 37 °C for 24 h
before being processed for immunoblotting analyses. Such heat
shock caused induction of Hsp70 in control but not antisense
Hsp70 transfectants, indicating the effectiveness of the anti-
sense Hsp70 construct (Fig. 8A). Our results also revealed that
heat shock alone neither influenced expression (Fig. 8A) nor
activity (Fig. 8B) of endogenous DLK in both CHIP/ and
CHIP/ cells. As expected from the above findings, a reduc-
tion of endogenous DLK levels was only detected in CHIP/
cells after treatment with okadaic acid (Figs. 8, A and B). How-
ever, when these cells were transfected with the antisense con-
struct (Fig. 8A) or exposed to lactacystin (Fig. 8B) before incu-
bationwith okadaic acid, no noticeable decrease in endogenous
DLK levels was observed. Therefore, Hsp70 appears essential
for CHIP-dependent proteasomal degradation of endogenous
DLK once it is activated by okadaic acid.
DISCUSSION
Like all members of the MLK family, DLK acts as a key com-
ponent of the JNK signaling pathway (1, 48). Although signifi-
cant progress has been achieved in the past few years in our
understanding of how DLK regulates the JNK pathway, very
little is known about the identity of its physiological agonists
and the mechanisms responsible for its own regulation. In this
study we report that the active form of DLK is targeted to the
proteasome for degradation by the stress-inducible protein
Hsp70 and its associated co-chaperoneCHIP.Hsp70 belongs to
a subfamily of Hsps that have been recognized as molecular
chaperones due to their ability to facilitate the folding andmat-
uration of key regulatory proteins, such as nuclear receptors,
kinases, and transcription factors (49). By analogy to other Hsp
familymembers, Hsp70 is induced in response to a wide variety
of chemical and physiological stresses, including those involved
in JNK activation, and its expression provides protection
against cell death (26, 27, 29). Themechanisms that account for
the cytoprotective activity of Hsp70 within the cell appear to be
highly dependent on its ability to prevent protein aggregation
and to induce refolding of damaged proteins (50). In addition,
recent evidence has accumulated to show that Hsp70 can
inhibit cell death by directly regulating the activity of proteins
that are involved in various aspects of apoptosis. For instance, it
has been reported that Hsp70 blocks both caspase-dependent
and caspase-independent cell death through interactions with
key apoptotic effector molecules, including apoptotic activat-
ing factor-1 (Apaf1) (51–53) and apoptosis-inducing factor
(AIF) (54). Interactions betweenHsp70 and kinases of signaling
FIGURE 7. Endogenous DLK undergoes CHIP-dependent ubiquitination
and degradation in its active form. CHIP/ and CHIP/ cells were incu-
bated in the presence or absence of lactacystin (10 M) for 3 h followed by
concurrent incubation for 2 h with 400 nM okadaic acid. Cells were subse-
quently lysed and subjected to immunoprecipitation (IP) with the DLK anti-
serum. Immune complexes were subjected to Western blotting (WB) with an
antibody to ubiquitin (Ub). DLK protein levels were determined by probing
the lysates with the DLK antiserum. DLK activity was determined in the lysates
from these cells by an immunocomplex kinase assay using myelin basic pro-
tein (MBP) as a substrate. As a control for protein loading, immunoblots were
probed in parallel with an anti-actin antibody.
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pathways that transduce stress signals have also been observed.
Park et al. (55) have found that Hsp70 can inhibit JNK activa-
tion in cells exposed to UV irradiation and that this inhibitory
function is linked to the Hsp70 ability to directly bind JNK and
suppress its association with and phosphorylation by MKK4.
The anti-apoptotic activity of Hsp70 is also reflected by its
capacity to interact with apoptosis signal-regulating kinase 1, a
mitogen-activated protein kinase kinase kinase of the JNK and
p38 MAPK (mitogen-activated protein kinase) signaling path-
ways that is required for cytokine- and stress-induced apoptosis
(56). In this case, Hsp70 binding prevents both oligomerization
of apoptosis signal-regulating kinase 1 (ASK1), an event
required for its activation, as well as
ASK1-dependent apoptosis (57).
In mammalian cells Hsp70 inter-
acts with a multitude of co-chaper-
ones that regulate its activity and
substrate affinity in a positive or
negative manner (29). Such interac-
tions have also been suggested to
modulate Hsp70 activity by mediat-
ing its recruitment to specific pro-
teins, protein complexes, and sub-
cellular compartment (43). Hsp70
co-chaperones, such asHsp40,Hop,
and BAG-1, have been shown to
serve as interaction partners for
protein involved in signal transduc-
tion, growth control, and cell differ-
entiation as well as apoptosis (58–
60). Hsp70 also cooperates with a
group of co-chaperones that have
degradatory functions (61). One
example is CHIP, a protein that
interacts with the C terminus of
Hsp70 via a tetratricopeptide repeat
domain and negatively regulates its
ATPase activity (33). CHIP also acts
as a U-box type E3 ubiquitin ligase
that promotes the polyubiquitina-
tion and subsequent degradation of
Hsp70 substrates, such as the glu-
cocorticoid hormone receptor and
the protein kinase Raf-1 (41). Thus,
through its association with CHIP,
Hsp70 is converted from a protein
folding machine into a specific deg-
radation factor (41). The results
presented here provide strong evi-
dence that DLK, when activated,
serves as a new molecular target for
the degradative activity of the
Hsp70-CHIP complex. Initial sup-
port for this conclusion came from
data demonstrating that exog-
enously expressed wild-type DLK,
which exists as a constitutively acti-
vated protein, but not kinase-defec-
tive DLK was able to associate with both endogenous Hsp70
and endogenous CHIP in COS-7 cells. The DLK association
with Hsp70 could be apparently modulated by posttransla-
tional events such as chemical modifications of specific amino
acids, given that no direct interaction was observed in vitro
between recombinant forms of these proteins. Alternatively, it
is also possible that Hsp70 and DLKmay be physically linked in
COS-7 cells by one ormore intermediatemolecules which pos-
sess the ability to interact with both proteins. By using transfec-
tion-based experiments, we further show that overexpression
of Hsp70 in COS-7 cells dramatically down-modulates the
steady-state levels of exogenously expressed wild-type DLK,
FIGURE 8. Hsp70 down-regulation impairs the CHIP-dependent degradation of endogenous DLK. A,
CHIP/ and CHIP/ cells transiently transfected with an empty vector (5 g) or an antisense Hsp70
mRNA-expression plasmid (5 g) were heat-shocked at 43 °C for 2 h and allowed to recover at 37 °C for 24 h. At
the end of the recovery period, cells were left untreated or were treated with 400 nM okadaic acid for 2 h. Cells
were subsequently lysed and subjected to immunoblot analysis (WB) with antibodies to DLK, Hsp70, and actin.
B, CHIP/ and CHIP/ cells were heat-shocked at 43 °C for 2 h and allowed to recover at 37 °C for 24 h. At the
end of the recovery period cells were left untreated or were treated with 10 M lactacystin for 3 h before
incubation with 400 nM okadaic acid for 2 h. Cells were subsequently lysed and subjected to immunoblot
analysis with antibodies to DLK, Hsp70, and actin. DLK activity was determined in the lysates from these cells by
an immunocomplex kinase assay using myelin basic protein (MBP) as a substrate.
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whereas its kinase-defective variant remains stable under the
same conditions. This finding is particularly significant because
it suggests that Hsp70 antagonizes DLK expression only when
its kinase domain is functionally active. In addition, the ATPase
activity of Hsp70, which is critical for its role in protein refold-
ing, is not required for its effects onDLK since amutant form of
Hsp70with theATPase domain deletedwas as effective aswild-
type Hsp70 in promoting DLK down-regulation. Interestingly,
the effects that Hsp70 has on wild-type DLK were blocked by
treatment of cells with the proteasome inhibitor lactacystin or
expression of a ubiquitin mutant incapable to form polyubiq-
uitin chains, indicating the involvement of the ubiquitin-pro-
teasome proteolytic pathway as the root cause of DLK down-
regulation. Because Hsp70-induced DLK degradation was also
reversed in COS-7 cells by a co-expressedCHIPmutant lacking
ubiquitin ligase activity, we then propose that CHIP may act as
an important regulator of this process. In accordance with this
possibility, it has been found that Hsp70 fails to induce degra-
dation of wild-type DLK when both proteins are co-expressed
in CHIP/ cells. However, adding back CHIP restores Hsp70
ability to down-modulate wild-type DLK to levels comparable
with that seen in CHIP/ cells. Thus, these results identify
CHIP as the ubiquitin ligase involved in the Hsp70-induced
degradation of exogenously expressed DLK.
An important observation of this study is thatHsp70 andCHIP
also cooperate to promote the proteasomal degradation of endo-
genously expressed DLK. This conclusion is supported by the fol-
lowing arguments. First, endogenous DLK was ubiquitinated in
CHIP/ but not CHIP/ cells. Second, okadaic acid, a serine/
threonine phosphatase inhibitor that stimulates DLK activity in
both CHIP/ and CHIP/ cells, promoted down-regulation of
endogenous DLK only in CHIP/ cells. Third, treatment of
CHIP/ cells with the proteasome inhibitor lactacystin before
okadaic acid stabilized endogenousDLKand favored the accumu-
lation of ubiquitinated DLK conjugates. Finally, down-regulation
of endogenous Hsp70 protein levels with an Hsp70 antisense was
sufficient to prevent DLK degradation induced by okadaic acid in
CHIP/ cells. Therefore, our results indicate that endogenous
DLK undergoes CHIP-dependent proteasomal degradation once
it is activated by okadaic acid and suggests that Hsp70 is required
for this process.
DLK is the first example of a MLK family member whose
protein levels aremodulated byHsp70/CHIP-mediated protea-
somal degradation. The significance of this observation is cur-
rently unknown, but degradation of proteins via the protea-
some is instrumental to various basic cellular processes, such as
proliferation, cell cycling, differentiation, gene expression, and
signal transduction (62). Recent work has also established that
the proteasome system plays a pivotal role in the regulation of
apoptosis by modulating the levels of proteins that have either
pro-apoptotic or anti-apoptotic properties (63). Especially
important among these are the tumor suppressor p53 (64), the
Bcl-2 family member Bax (65), and the inhibitor of apoptosis
(IAP) proteins (66). It is clear from our data that activation of
both exogenous and endogenous DLK serves as an essential
trigger mechanism for its proteasomal-dependent proteolysis.
Because DLK kinase activity modulates phosphorylation of
DLK in vivo, as reported previously (24), it will be very interest-
ing in future work to examine whether a specific phosphoryla-
tion site(s) of DLK serves, at least in part, as a recognition signal
for the degradation machinery. Serine phosphorylation has
been found to be required for ubiquitination and degradation of
many cell proteins that control proliferation and apoptosis,
including the NF-B inhibitor IB, which in its phosphoryla-
ted form is targeted to the proteasome by the small heat shock
protein Hsp27 (67).
In conclusion, the findings presented here point to an impor-
tant role for the Hsp70/CHIP degradation complex in the neg-
ative regulation of DLK protein levels. It is possible that the
control of DLK levels by this complex might function as a
mechanism exploited by the cell to down-modulate DLK when
it becomes phosphorylated and activated in response to appro-
priate stimulation. Given the role of DLK as a component of the
JNK pathway, it is tempting to speculate that its degradation
after activation represents a novel regulatory mechanism by
which Hsp70 modulates JNK-signaling events.
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